Venous thromboembolism (VTE).

GUIDELINE TITLE
Venous thromboembolism (VTE).

BIBLIOGRAPHIC SOURCE(S)
University of Michigan Health System. Venous thromboembolism (VTE). Ann Arbor (MI): University of Michigan Health System; 2009 Feb. 13 p. [10 references]

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: University of Michigan Health System. Venous thromboembolism (VTE). Ann Arbor (MI): University of Michigan Health System; 2004 Aug. 11 p. [5 references].

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERTNote from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

December 3, 2008 - Innohep (tinzaparin): The U.S. Food and Drug Administration (FDA) has requested that the labeling for Innohep be revised to better describe overall study results which suggest that, when compared to unfractionated heparin, Innohep increases the risk of death for elderly patients (i.e., 70 years of age and older) with renal insufficiency. Healthcare professionals should consider the use of alternative treatments to Innohep when treating elderly patients over 70 years of age with renal insufficiency and deep vein thrombosis (DVT), pulmonary embolism (PE), or both.

abrir aquí para acceder al documento AHRQ NGC completo:
Venous thromboembolism (VTE).